IPOs

  • IPO investors pay up for Freeline as biotech fever rises

    IPO investors pay up for Freeline as biotech fever rises

    Freeline, the UK gene therapeutics company, has priced its IPO on the Nasdaq exchange at the top of the pricing range, with investors willing to pay a big premium for the stock. The company is the latest deal in a global biotech issuance spree that has passed $60bn.

  • ECM bankers pray macro risk won’t disrupt deals

    ECM bankers pray macro risk won’t disrupt deals

    Equity capital markets bankers are hoping that global markets maintain the extraordinary bullishness of the last few weeks in what should prove a busy final quarter of the year for issuance. But an unholy trinity of risks are causing concern, particularly for IPOs.

  • Covid-19 spikes to wreak havoc in capital markets

    Covid-19 spikes to wreak havoc in capital markets

    Capital markets are preparing for a resurgence in Covid-19 cases as infection rates rise in the US and Europe. Bankers and investors are digging in for a longer pandemic than they hoped for and capital raising plans are set for a complete overhaul, report Sam Kerr, Lewis McLellan and Tyler Davies.

  • Li Auto shrugs off China-US tensions with IPO success

    Li Auto shrugs off China-US tensions with IPO success

    Electric vehicle manufacturer Li Auto sealed a scorching $1.1bn Nasdaq IPO this week, pricing above the marketed range to make it the largest US listing by a Chinese company in nearly two years. The deal proved there is still interest among mainland firms to list in the US, despite rising hostilities between the two countries, writes Jonathan Breen.

IPO Archive